UMB Bank’s Iovance Biotherapeutics IOVA Stock Holding History

UMB Bank’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-355	Closed	-$4K	–	1865
2022 Q2	$4K	Hold	355	–	–	﹤0.01%	1621
2022 Q1	$6K	Hold	355	–	–	﹤0.01%	1623
2021 Q4	$7K	Buy	+355	New	+$7.82K	﹤0.01%	1542

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

UMB Bank's IOVA Position: Q3 2022 in Review

UMB Bank sold out of Iovance Biotherapeutics (IOVA) in Q3 2022, closing a stake of 355 shares — an estimated $4K sold.

UMB Bank first reported a position in IOVA in Q4 2021 and held it in 3 quarters. The position peaked at $7K in Q4 2021. 242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

UMB Bank reported no remaining Iovance Biotherapeutics position as of Q3 2022 after selling out during the quarter.
UMB Bank sold 355 Iovance Biotherapeutics shares in Q3 2022, an estimated $4K.
UMB Bank first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 3 quarters.
UMB Bank's Iovance Biotherapeutics position peaked at $7K in Q4 2021.
242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on UMB Bank's 13F filing for Q3 2022, filed 13 Oct 2022.